| 证券代码：688131 | 证券简称：皓元医药 公告编号：2025-104 | | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | 上海皓元医药股份有限公司 关于向不特定对象发行可转换公司债券募投项目调 整部分实施地点及延期的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 上海皓元医药股份有限公司（以下简称"皓元医药"或"公司"）于2025 年8月26日召开第四届董事会审计委员会第五次会议、于2025年8月27日召开第 四届董事会第十一次会议，审议并通过了《关于向不特定对象发行可转换公司 债券募投项目调整部分实施地点及延期的议案》，同意公司将向不特定对象发 行可转换公司债券募集资金投资项目（以下简称"募投项目"）"高端医药中间 体及原料药CDMO产业化项目（一期）"（以下简称"CDMO项目"）部分车 间、公用工程及辅助设施的实施地点在原厂区内进行调整，并将该项目达到预 定可使用状态的时间延期至2029年6月。公司保荐机构民生证券股份有限公司 （以下简称"保荐机构"）对该事项出具了无 ...

Core Viewpoint - Haoyuan Pharmaceutical (688131.SH) reported a significant increase in revenue and net profit for the first half of 2025, indicating strong financial performance and growth potential [1] Financial Performance - The company achieved a total operating revenue of 1.311 billion yuan, representing a year-on-year growth of 24.2% [1] - The net profit attributable to shareholders reached 152 million yuan, showing a remarkable year-on-year increase of 115.55% [1] - Basic earnings per share were reported at 0.72 yuan [1] Dividend Distribution - The company proposed a cash dividend of 0.8 yuan per 10 shares (tax included) for all shareholders [1]

Market Overview - The recombinant protein sector experienced a decline of 1.01%, ranking among the top losers in concept sectors as of the market close on August 28 [1] - Notable declines within the sector included companies such as Aladdin, Bory Pharmaceutical, and Zhongyuan Union, while Chengdu XianDao, Dezhan Health, and Betta Pharmaceuticals saw increases of 7.44%, 2.38%, and 2.02% respectively [1] Concept Sector Performance - The top-performing concept sectors included Copper Cable High-Speed Connection (+5.61%), Co-Packaged Optics (+5.13%), and F5G Concept (+5.12%), while the recombinant protein sector was among the laggards with a decline of 1.01% [2] Capital Flow Analysis - The recombinant protein sector faced a net outflow of 1.348 billion yuan, with 41 stocks experiencing net outflows, and 6 stocks seeing outflows exceeding 50 million yuan [2] - Bory Pharmaceutical led the outflows with a net outflow of 548 million yuan, followed by Zhifei Biological, Hualan Biological, and Zhongyuan Union with net outflows of 149 million yuan, 88.91 million yuan, and 77.72 million yuan respectively [2] Individual Stock Performance - Bory Pharmaceutical reported a decline of 6.63% with a turnover rate of 5.33% and a net outflow of 547.71 million yuan [3] - Chengdu XianDao was the standout performer in the sector, increasing by 7.44% despite a net outflow of 203.74 million yuan [3] - Other notable stocks with significant net inflows included Dezhan Health (+2.38%) with a net inflow of 46.14 million yuan, Haoyuan Pharmaceutical (+1.82%) with a net inflow of 18.75 million yuan, and Maimai Biological (+1.82%) with a net inflow of 18.75 million yuan [4]

Group 1 - The company, Haoyuan Pharmaceutical, announced a provision for asset and credit impairment losses totaling 66.2 million yuan for the first half of 2025, which will reduce the total profit by the same amount [1] - The net profit attributable to the parent company will decrease by 61.5 million yuan due to this provision [1] - The company's total equity will also be reduced by 61.5 million yuan for the same period [1] Group 2 - For the year 2024, Haoyuan Pharmaceutical's revenue composition indicates that 99.27% comes from research and experimental development, while other businesses account for only 0.73% [1] - The company's market capitalization is currently 12.8 billion yuan [2]

Core Insights - Haoyuan Pharmaceutical (688131.SH) reported a revenue of 1.311 billion yuan for the first half of 2025, marking a year-on-year growth of 24.20%, with overseas revenue reaching 560 million yuan, up 39.78% [1] - The company achieved a net profit of 152 million yuan, reflecting a significant year-on-year increase of 115.55%, and a gross margin of 49.1%, up 3.7 percentage points [1] - The company emphasizes a long-term strategy focused on "industrialization, globalization, and branding," aiming to enhance customer value and operational efficiency [1] Business Performance - The life sciences reagent segment saw robust growth, generating 904 million yuan in revenue, a 29.2% increase year-on-year, with a gross margin of 63.0% [3] - The company has a cumulative reserve of approximately 147,000 types of life science reagents, maintaining a leading position in product variety and diversity [3] - The CDMO (Contract Development and Manufacturing Organization) business achieved revenue of 399 million yuan, a 13.6% increase, with a strong order backlog of 590 million yuan, up over 40% year-on-year [4] Industry Trends - The global biopharmaceutical market is projected to exceed $1.5 trillion, with China accounting for over 20%, translating to a market size of 3.2 trillion yuan and a compound annual growth rate of 17.6% from 2020 to 2025 [2] - The industry is undergoing significant transformation, with advancements in dual antibodies and AI-driven drug development gaining traction [2] Global Expansion - Haoyuan Pharmaceutical is accelerating its globalization efforts, establishing a multi-brand matrix and global sales network, with overseas revenue reaching 560 million yuan, accounting for 43.0% of total revenue [6][7] - The company is actively expanding its presence in the U.S., Europe, Japan, and South Korea, while also focusing on high-end markets in North America and Europe [7] AI Integration - The company is enhancing its AI drug development strategy, integrating various computational drug design algorithms to create a comprehensive drug screening platform [8][9] - Haoyuan Pharmaceutical aims to build a three-tier intelligent screening system combining AI algorithms, organoid models, and large-scale compound libraries, facilitating a full-chain system from basic research to industrial application [8][9]

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-101 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 公司于 2025 年 8 月 27 日召开第四届董事会第十一次会议，审议通过了《关 于公司计提资产减值准备的议案》，现将相关情况公告如下： 一、本次计提资产减值准备情况概述 为客观反映公司财务状况和资产价值，根据《企业会计准则》及公司会计政 策等相关规定，公司及子公司对截至 2025 年 6 月 30 日的资产进行了减值测试， 基于谨慎性原则，公司 2025 年 1-6 月计提各项资产减值准备合计 6,620.09 万元， 具体情况如下： 单位：人民币万元 | 项目类别 | 本期计提金额 | | --- | --- | | 信用减值损失-应收账款坏账准备 | 643.31 | | 信用减值损失-其他应收款坏账准备 | -119.90 | | 小计 | 523.41 | | 资产减值损失-存货跌价准备 1 | 6,147.09 | 上海皓元医药股份有限公司 关于公司计提资产减值准备的公告 本公司董事会及全体董事保证本公告内容不 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-102 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | | 对外担保逾期的累计金额（万元） | | | 0 | | --- | --- | --- | --- | | 截至 2025 年 8 27 | 月 | 日上市公司及 | | | 其控股子公司对外担保总额（万 | | | 66,080.13 | | 元） | | | | | 对外担保总额占上市公司最近一 期经审计净资产的比例（%） | | | 22.96 | | 特别风险提示（如有请勾选） | | 100% | □对外担保总额超过最近一期经审计净资产 | | | | | □担保金额超过上市公司最近一期经审计净资 | | | | 产 50% | | | | | | □对合并报表外单位担保金额达到或超过最近 | | | | | 一期经审计净资产 30%的情况下 | | | | | 对资产负债率超过 70%的单位提供担保 | 一、担保情况概述 上海皓元医药股份有限公司 关于子公司拟申请银行授信并由公司为子公司银行 授信提供担保的 ...

| 证券代码：688131 | 证券简称：皓元医药 | 公告编号：2025-107 | | --- | --- | --- | | 转债代码：118051 | 转债简称：皓元转债 | | 投资者可于 2025 年 9 月 19 日（星期五）至 9 月 25 日（星期四）16:00 前登 录 上 证 路 演 中 心 网 站 首 页 点 击 " 提 问 预 征 集 " 栏 目 或 通 过 公 司 邮 箱 hy@chemexpress.com.cn 进行提问。公司将在说明会上对投资者普遍关注的问题 进行回答。 上海皓元医药股份有限公司（以下简称"公司"）于 2025 年 8 月 29 日在上 海证券交易所网站（www.sse.com.cn）披露公司 2025 年半年度报告、半年度利 润分配方案。为便于广大投资者更全面深入地了解公司 2025 年半年度经营成果、 财务状况、现金分红事项，公司计划于 2025 年 9 月 26 日（星期五）13:00-14:30 举行 2025 年半年度业绩暨现金分红说明会，就投资者关心的问题进行交流。 一、说明会类型 上海皓元医药股份有限公司 关于召开 2025 年半年度业绩暨现金分 ...

转 债 简 称 ： 皓 元 转 债 转 债 代 码 ： 1 1 8 0 5 1 股 票 简 称 ： 皓 元 医 药 股 票 代 码 ： 6 8 8 1 3 1 2025年度 专项行动方案半年度评估报告 "提质增效重回报" Contents 目 录 | 01 | Page | 聚焦主业深耕 | 05 | 厚植股东回报 Page | | --- | --- | --- | --- | --- | | | 02-06 | 厚积核心竞争优势 | | 15-16 共享公司高质量发展成果 | | 02 | Page | 守正创新赋能 | 06 | 践行ESG理念 Page | | | 07-10 | 驱动新质生产力跃升 | | 17 打造可持续发展新动能 | | 03 | Page | 完善治理体系 | 07 | 其他 Page | | | 11-13 | 提升规范运作水平 | | 18 说明 | 完善治理体系 提升规范运作水平 Page 03 11-13 提高信披质量 加强投资价值传递 Page 04 14 年 度 提质增效重回报 专项行动方案 半年度评估报告 " " 上海皓元医药股份有限公司 Shanghai Hao ...

2025 年 6 月 4 日，公司可转换公司债券"皓元转债"进入转股期。截至 2025 年 8 月 27 日，"皓元转债"累计转股 10,479 股，公司注册资本增加 10,479.00 元。 公司于 2025 年 6 月 30 日完成了 2022 年限制性股票激励计划首次授予部分 第三个归属期以及预留部分第二个归属期的归属登记手续，该部分股票已于 2025 年 7 月 8 日正式上市流通。本次归属的股票数量为 648,570 股股份。公司总 股本增加 648,570 股，注册资本增加 648,570.00 元。具体内容详见公司于 2025 年 7 月 3 日在上海证券交易所网站（www.sse.com.cn）披露的《上海皓元医药股 份有限公司关于 2022 年限制性股票激励计划首次授予部分第三个归属期以及预 留部分第二个归属期归属结果暨股份上市公告》（公告编号：2025-081）。 公司分别于 2025 年 3 月 26 日、2025 年 4 月 18 日召开第四届董事会第四次 会议、第四届监事会第四次会议、2024 年年度股东大会，审议通过了《关于药 | 证券代码：688131 | 证券简称：皓元医药 | ...